HEALTH TECHNOLOGY

CANet and Clearbridge Mobile to Launch COVID-19 Healthcare Web App

Clearbridge Mobile | November 04, 2020

Clearbridge Mobile is glad to have assumed an essential function in helping the Cardiac Arrhythmia Network of Canada (CANet) dispatch, VIRTUES, an online electronic application created to decrease crisis division visits and improve COVID-19 patient-driven consideration. With a considerable lot of Canada's telehealth arrangements under gigantic strain because of the pandemic, the requirement for an advanced arrangement was unavoidable and introduced an awesome open door for the two associations to accomplice and aggregately uphold Canadian residents and forefront medical services experts.

 

With a demonstrated history of meeting forceful timetables, past experience working with ventures in the medical care area across Canada and the United States, and industry-explicit aptitude in portable and web application improvement, banding together with Clearbridge Mobile was a conspicuous decision for this undertaking.

 

"As a made-in-Canada solution, partnering with a local North American vendor was extremely important to us," says CANet CEO and Scientific Director Dr. Anthony Tang. "This ensured we would have unrestricted access to their team of experts whenever needed, and allowed for open and transparent communication. Clearbridge Mobile was very customer-centric and dedicated to a refined process that helped us achieve success in launching this app."

 

The web-application dispatched inside its four-week cutoff time and has different highlights that empower CANet's VIRTUES stage to assume a characterized function in COVID-19 patient-driven consideration. Excellencies permits patients and medical services experts to all the more likely screen, emergency, and deal with their therapy while restricting eye to eye cooperation.

 

Key features include:

The ability to record, monitor, and track symptoms within the platform

The ability to display patterns in the symptom progression of individual patients

The ability for healthcare professionals to communicate care plans remotely

The ability for nurses to alert and triage patients' recovery

 

"Time was of the essence with this project," says Clearbridge Mobile CEO Deepak Chopra. "Given the circumstances, it was imperative for us to bring the app to market ASAP. Our design thinking approach, and agile software development expertise allowed us to work quickly and iteratively to leverage our in-house team's knowledge to meet this demand. As a company, it is our goal to develop applications that have a positive impact on the lives of the user, and I think this platform holds tremendous value for both healthcare professionals and COVID-19 positive patients."

 

The partnership with Clearbridge Mobile empowered CANet to approach industry specialists with a profound comprehension of the necessities of the medical care area and in the standards of communication configuration, bringing about a client experience that understands all clients, while as yet tending to the operational effect on emergency clinics, and facilities to diminish failures and expenses.

 

About Clearbridge Mobile

Clearbridge Mobile is an award-winning full-stack mobile app development company that provides user-centric design and engineering services to the world's top enterprises, helping them meet their digital initiatives. Clearbridge Mobile is dedicated to building better, healthier relationships between you and your customers with best-in-class mobile solutions. 

 

About Cardiac Arrhythmia Network of Canada

CANet is a Pan-Canadian multidisciplinary and multi-sectoral research and development network of investigators, well-positioned industry partners, patients, caregivers, and healthcare providers focused on arrhythmia research, technology development and commercialization, and digital transformation activities. 

Spotlight

Welcome to this Medical Appraisal Skills Video Workshop.
This is one of a series of short films intended to explore some of the challenges presented by medical appraisal conversations, and to encourage you to consider helpful behaviours, strategies, and mind-sets for these important meetings. The purpose of this film is to explore how we can encourage doctors to reflect on their practice, and use multisource feedback to help create a personal development plan.


Other News
MEDICAL DEVICES

GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

GeneQuantum Healthcare | May 16, 2022

GeneQuantum Healthcare Co., Ltd. a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum's pipelines in the clinical stage. They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugateboth with global intellectual property rights. "The core technologies that we have focused on since the founding of GeneQuantum, bring the company into the harvest period for exciting next generation bioconjugate drugs. The EC approval of GQ1005 and GQ1007 in Australia is an important milestone for the company. More than once, GeneQuantum's enzymatic site-specific conjugation platform and the stable linker technology have demonstrated the advantages through several IND enabled drug candidates. GeneQuantum conjugation technologies are widely compatible to different molecular modalities with various Mechanism of Action. Committed to the core value of "breakthrough for humanity", GeneQuantum is dedicated to developing safe, effective, and affordable novel therapeutics for patients with cancer around the world." Dr. Gang Qin, founder, Chairman and Chief Executive Officer About GeneQuantum Healthcare Co., Ltd. GeneQuantum Healthcare Co., Ltd. is a global biotechnology company dedicated to the development of innovative biotherapeutics. The company is focused on the development of next generation bioconjugate therapeutics to address the unmet medical needs of patients globally. This press release contains statements relating to GeneQuantum's future business, future events or developments, and related statements may constitute forward-looking statements. Statements are based on current expectations and assumptions that are subject to risks and uncertainties, which may cause actual results to differ materially. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, follow-up clinical data and analysis; factors that may cause any delay, transfer or change; regulatory authority decision whether and when to approve drug applications; factors that may lead actual results to seriously deviate from current expectations, etc. No forward-looking statement can be guaranteed. Except as required by applicable laws, GeneQuantum assumes no obligation to update or revise any forward-looking information or statements.

Read More

HEALTH TECHNOLOGY

NUTEX HEALTH ANNOUNCES TWO NEW FULLY FUNCTIONAL MICRO HOSPITALS

Nutex Health, Inc. | May 17, 2022

Nutex Health Inc. a physician-led, technology-enabled healthcare services company comprised of a hospital division with 21 facilities in 8 states and a primary care-centric, risk-bearing population health management division, announced two new fully operational micro hospitals. The first hospital, New Braunfels ER & Hospital, is in New Braunfels, Texas, located about 30 miles northeast of San Antonio. The state-of-the-art facility is open 24/7, 365 days a year, and includes an emergency room with 9 private exam rooms staffed with board-certified physicians and 4 private inpatient beds. The hospital provides both adult and pediatric care, and has the most advanced imaging and laboratory equipment, including CT, X-Ray and ultrasound with rapid radiological reports. The second hospital, East Valley ER & Hospital, is in Gilbert, Arizona, located about 21 miles southeast of Phoenix. The state-of-the-art hospital is open 24/7, 365 days a year, and includes an emergency room with 14 private exam rooms and 14 private inpatient beds. The hospital provides both adult and pediatric care, and has the most advanced imaging and laboratory equipment, including MRI, CT, X-Ray and ultrasound. Nutex currently anticipates opening 3 more facilities in 2022, with another 17 facilities either under construction or in advanced planning stages and anticipated to open in 2023 and 2024. There can be no assurance that these additional facilities will open in the anticipated timing or that they will open at all. Nutex micro hospitals focus on ensuring that patients receive a premium patient experience. Our hospitals feature short ER wait times averaging 15 minutes from entering the door to seeing a physician, high-quality care, lower nursing- and physician-to-patient staffing ratios and faster discharge times. Physicians, nurses and other employees are incentivized to provide quality, compassionate care to their patients. Nutex micro hospitals consistently have better outcomes and high patient satisfaction scores, with well over 1000 five-star Google reviews. "We are excited to continue to expand Nutex's network of micro hospitals across the country. Both New Braunfels and Gilbert are vibrant and rapidly growing suburbs of major metropolitan areas. Our goal is to provide high-quality acute medical care to the populations of these communities." Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health "Entering the medical field, my goal was always to try to revolutionize the way healthcare is delivered to our patients. Our unique model allows physicians and nurses to retake control of patient care," stated Trey Allen, M.D., Medical Director at New Braunfels ER & Hospital. "We are committed to working with the community to make sure they can receive the healthcare they deserve." "As physicians, we saw how healthcare was being delivered, and we felt we could do better. We felt the humanity and compassion were absent from many medical interactions. We value and respect our patients, and treat them as family," stated Daniel Stites, M.D., Medical Director at East Valley ER & Hospital. About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. is a physician-led, technology-enabled healthcare services company with approximately 1500 employees nationwide and is partnered with over 800 physicians. The Company has two divisions a Hospital division and a Population Health Management division. The hospital division owns and operates 21 facilities in eight different states. The division implements and operates different innovative health care models, including micro hospitals, specialty hospitals and hospital outpatient departments. The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organizations, we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently. Safe Harbor Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include the ability to realize the anticipated benefits of the transaction, significant transaction costs and unknown liabilities and litigation and regulatory risks related to the transaction. In addition, forward-looking statements are subject to additional uncertainties and risks facing the Company, including but not limited to, economic conditions, dependence on management, dilution to stockholders, lack of capital, changes in laws or regulations, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Read More

MEDICAL DEVICES

BD Acquires Scanwell Health, Inc. to Expand and Scale Digital At-Home Testing

BD | December 22, 2021

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced it has completed the acquisition of privately held Scanwell Health Inc., a leader in smartphone-enabled at-home medical tests.BD collaborated with Scanwell to develop the app used with the recently launched BD Veritor™ At-Home COVID-19 Test, the first at-home COVID-19 test that uniquely uses a smartphone camera and app to capture and interpret results, eliminating the human subjectivity in other visually read at-home antigen tests. Scanwell will become the foundational digital platform upon which BD plans to develop at-home diagnostic tests for a range of infectious diseases including COVID-19/influenza A+B, group A strep and additional menu for detecting infections and managing chronic disease. "The COVID-19 pandemic has accelerated the shift to new care settings, and BD is ready to deliver a smart, connected at-home diagnostic ecosystem to support traditional and telehealth providers and consumers. This acquisition will enable us to expand and scale our digital capabilities in-house to speed time to market for transformative at-home solutions now and in the future." Dave Hickey, president of Life Sciences for BD The Scanwell app is a key differentiator in the market for at-home COVID-19 testing. To date, no other company uses the phone's camera to capture the image of the test that is then analyzed and interpreted by the app. Other COVID-19 home tests use smartphones as part of their process, but BD Veritor™ At-Home COVID-19 Test is the first and only test to use the smartphone as the analyzer to digitally interpret the test results and provide a definitive POSITIVE or NEGATIVE digital display of testing results. The app also has the capabilities to securely store and report test results to organizations, including businesses, public health authorities and schools. The results of tests are stored in the app and can be referenced and displayed at any time by simply logging into the app. Terms of the transaction were not disclosed. The transaction is expected to be immaterial to BD's fiscal 2022 financial results. Scanwell financial results will be reported under the Integrated Diagnostic Solutions business within the Life Sciences segment. About the BD Veritor™ At-Home COVID-19 Test The BD Veritor™ At-Home COVID-19 Test has not been FDA cleared or approved; but has been authorized by FDA under Emergency Use Authorization (EUA). This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Read More

FUTURE OF HEALTHCARE

SandboxAQ and Mount Sinai Health System Collaborate on Data Protection

Sandbox AQ | March 24, 2022

Sandbox AQ, an enterprise SaaS company leveraging quantum tech and AI, announced a collaboration with Mount Sinai Health System to launch Post-Quantum Cryptography solutions, a broad security technology solution to protect patient data against current and future cybersecurity threats. Sandbox has developed SaaS-based enterprise modules that incorporate the latest encryption protocol standards recently ratified by NIST (National Institute of Standards and Technology). Through Sandbox AQ, Mount Sinai Health System will incorporate PQC protocols into its network to provide increased security for millions of customers and their sensitive data. "Our collaboration with Sandbox AQ propels our security and technology strategies forward, enabling us to deliver advanced, secure cutting-edge products to our patients. Protecting patient data against cyber threats is incredibly important to us." Kristin Myers, Executive Vice President and Chief Information Officer at Mount Sinai Health System and Dean for Information Technology at Icahn School of Medicine at Mount Sinai "Quantum technology will quickly render today's RSA-based encryption obsolete, which is why it's imperative that we protect the world's sensitive data now against the next generation of cyberattacks," said Jack D. Hidary, CEO of Sandbox AQ, which officially launched today. "Mount Sinai is one of the first healthcare systems planning to implement PQC protocols into its health network to protect its customers and transform its business. We look forward to collaborating with them on this project." About SandboxAQ Sandbox AQ is an enterprise SaaS company delivering solutions at the nexus of quantum tech and AI. Based in Palo Alto, the inspiration for Sandbox AQ and some of the team originated at Alphabet Inc. in 2016. Sandbox AQ launched as an independent, venture-backed entity in 2022. About Mount Sinai Health System The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. We advance medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 free-standing joint-venture centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked in U.S. News & World Report's "Honor Roll" of the top 20 U.S. hospitals and among the top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Urology, and Rehabilitation. Mount Sinai Kravis Children's Hospital is ranked in U.S. News & World Report's "Best Children's Hospitals" among the country's best in four out of 10 pediatric specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked among the Top 20 nationally for ophthalmology. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek's "The World's Best Smart Hospitals" ranks The Mount Sinai Hospital as No. 1 in New York and top five globally, and Mount Sinai Morningside as top 20 globally, and "The World's Best Specialized Hospitals" ranks Mount Sinai Heart as No. 1 in New York and No. 4 globally and the Division of Gastroenterology as No. 3 globally, and the Division of Pulmonary Medicine as No. 6 globally.

Read More

Spotlight

Welcome to this Medical Appraisal Skills Video Workshop.
This is one of a series of short films intended to explore some of the challenges presented by medical appraisal conversations, and to encourage you to consider helpful behaviours, strategies, and mind-sets for these important meetings. The purpose of this film is to explore how we can encourage doctors to reflect on their practice, and use multisource feedback to help create a personal development plan.

Resources